Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Falco Holdings Co., Ltd. (4671:JPX), powered by AI.
Falco Holdings Co., Ltd. is currently trading at ¥2,565. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Falco Holdings Co., Ltd. on Alpha Lenz.
Falco Holdings Co., Ltd.'s P/E ratio is 14.1.
“Falco Holdings Co., Ltd. trades at a P/E of 14.1 (undervalued) with modest ROE of 7.5%.”
Ask for details →Falco Holdings Co., Ltd. is a company engaged in providing comprehensive diagnostic services across multiple sectors, primarily focusing on the healthcare and medical industries. The company's core function revolves around clinical laboratory testing and diagnostic analysis, which are critical components in the detection, diagnosis, and management of various diseases. Falco Holdings supports hospitals, clinics, and healthcare providers by delivering precise and timely diagnostic results, thereby playing an indispensable role in patient care and treatment planning. With a wide range of laboratory services, Falco Holdings Co., Ltd. is instrumental in enhancing the accuracy and efficiency of medical diagnostics. The company's offerings include molecular diagnostics, pathology testing, and preventive health screenings, all of which are crucial in the early detection and monitoring of health conditions. By leveraging advanced technological capabilities and a thorough understanding of medical science, Falco Holdings contributes significantly to the healthcare sector's sustainability and operational effectiveness. In the financial market, the company serves as a prominent entity reflecting the healthcare industry's growth and technological advancements, underlining the importance of innovation and precision in the evolving landscape of medical diagnostics.
“Falco Holdings Co., Ltd. trades at a P/E of 14.1 (undervalued) with modest ROE of 7.5%.”
Ask for details →Falco Holdings Co., Ltd. (ticker: 4671) is a company listed on JPX in the Healthcare sector (Diagnostics & Research). It has approximately 1,062 employees. Market cap is $27.1B.
The current price is 2,565 with a P/E ratio of 14.11x and P/B of 1.07x.
ROE is 7.49% and operating margin is 5.39%. Annual revenue is $43.3B.